Stoke Therapeutics
STOK· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +187.8% in FY2025
Ian F. Smith is the CEO of Stoke Therapeutics and was paid $27.0M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $288
Executives4
See all- 1Ian F. SmithChief Executive OfficerFY2025
- 2Edward M. Kaye, M.D.Former Chief Executive OfficerFY2025
- 3Jason HoittChief Patient OfficerFY2025
- 4Thomas LeggettChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allStoke Therapeutics paid its 4 named executives $34.4M in total in FY2025 (Dec). CEO Ian F. Smith was paid $27.0M of that.
| Name | |||
|---|---|---|---|
| Ian F. SmithChief Executive Officer | Not disclosed | Not disclosed | |
| Edward M. Kaye, M.D.Former Chief Executive Officer | |||
| Jason HoittChief Patient Officer | Not disclosed | Not disclosed | |
| Thomas LeggettChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Stoke Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Arthur A. LevinDirector · 10 yr on the boardIndependentNominating and Corporate Governance (Chair), Research and Development—Paid as an executive
- Seth L. HarrisonDirector · 10 yr on the boardIndependentCompensation, Research and Development—Paid as an executive
- Edward M. Kaye, M.D.Director · 8 yr on the boardNot independentResearch and Development—Paid as an executive
- Arthur O. TzianabosDirector · 7 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Jennifer C. BursteinDirector · 6 yr on the boardIndependentAudit (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 16, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Mar 18, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Mar 25, 2024 | FY2023 |
